GlassScriptPhysician profile
Lindsay M John
NPI 1184649105
$2,165.11
in general payments reported to CMS, 2019-2025
11 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $266 · 2021: $232 · 2022: $441 · 2023: $457 · 2024: $264 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872 · Education: $51.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.99 |
| Education | $51.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $635.16 | 2022-2025 | Nuzyra |
| Portola Pharmaceuticals, LLC | $352.62 | 2019-2020 | |
| Medtronic, INC. | $213.89 | 2021-2023 | Tyrx, Linq II, Micra |
| Cumberland Pharmaceuticals, INC. | $207.20 | 2019-2023 | Vibativ |
| Melinta Therapeutics, LLC | $154.03 | 2019-2024 | Kimyrsa, Orbactiv, Vabomere |
| Shionogi INC | $153.77 | 2022-2024 | Fetroja |
| Mayne Pharma Commercial LLC | $112.65 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $100.38 | 2024-2025 | Vowst |
| Insmed, INC. | $93.63 | 2020-2022 | |
| Gilead Sciences, INC. | $82.99 | 2021-2025 | |
| Abbvie INC. | $58.79 | 2022-2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.